Tuesday, August 23, 2022
Calyptus Pharmaceuticals, Inc., announced that it entered into an agreement with Provepharm SAS ("Provepharm"), to accelerate the development, marketing and distribution of a complex injectable product used in acute care settings. With the consummation of the transaction, Provepharm acquired global rights to the product from Calyptus and will take on all development activities and ultimately commercial distribution upon approval. Financial terms of the transaction were not disclosed.
Calyptus Co-founders - Sujeet Singh, Dr. Puiho Yuen and Shubhayu Sinharoy said, "We are thrilled to partner with Provepharm on this lead pipeline asset. We believe that combining Calyptus' know-how and R&D capability with Provepharm's institutional operational strength in the United States, along with its developmental capabilities, will provide patients with more options to affordable and accessible medication."
Matthieu Leuwers, Provepharm's Chief Business Development Officer said, "Provepharm strengthens its portfolio of sterile injectables in development to reinforce its product offering commercialized directly to hospital health care professionals in U.S.A. and Europe."
